Protective effect of crude polysaccharide from Pao-TianXiong derived from monkshood, against chronic renal failure in mice
Purpose: To investigate the effect of crude polysaccharide isolated from pao-tian-xiong on chronic renal failure in mice, and its monosaccharide composition.
Methods: Male Kunming mice were orally treated with adenine (211.5 mg/kg/day) for 7 days, followed by either crude polysaccharides (125, 250 or 500 mg/kg), or positive drug solution (jinguishenqi pill, 2000 mg/kg) for another 7 days (each group had 15 mice). Mice in normal and negative control groups were given saline. Mental and physical states, blood urine nitrogen (BUN) and serum creatinine (SCr), kidney morphological changes and organ indices were determined. Histopathological examination of spleen and kidney tissues was also performed. The monosaccharide composition of crude polysaccharide was determined by high-performance liquid chromatography (HPLC) and gas chromatography and mass spectrometry (GC-MS).
Results: Compared with negative control group, serum BUN (6.71 mmol/L vs. 8.61 mmol/L) and Cr (107.74 vs. 113.39 μmol/L) were significantly decreased by the crude polysaccharide isolate (p < 0.05), whereas epididymis index (0.2556 vs. 0.2135 %) and seminal vesicle index (0.5547 vs. 0.3945 %) were increased (p < 0.05). Histopathological examination showed that injuries to kidney, spleen, testis and epididymis decreased significantly. The crude polysaccharides contained mainly glucose, rhamnose, arabinose, galactose, mannose, galacturonic acid, glucuronic acid and xylose, and their contents ranged from 0.7 to 65 %.
Conclusion: These results suggest that the crude polysaccharides of Pao-tian-xiong ameliorates CRF symptoms in mice, thereby providing experimental evidence in support of its use as an anti-CRF drug.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.